COMPASS Pathways plc
COMP006
treatment-resistant depression (TRD)
Resolved
98days ago
Phase 3 readout · Mar 31, 2026
What's at stake
Phase 3 trial results for COMP006 in treatment-resistant depression (TRD) are due Mar 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Research and development expenses were $26.5 million for the three months ended March 31, 2026, compared with $30.9 million during the same period in 2025.”